Trial Profile
A Multi-national, Multi-center, Randomized, Double Blinded, Parallel-group Study to Assess the Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs NBP 608 (Primary) ; Varicella zoster virus vaccine live
- Indications Varicella zoster virus infections
- Focus Pharmacodynamics
- Sponsors SK Bioscience; SK Chemicals
- 06 May 2019 Status changed from active, no longer recruiting to completed.
- 18 Apr 2017 New trial record